- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04154605
ClariFix Rhinitis RCT (CR RCT)
ClariFix Rhinitis Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Coral Springs, Florida, United States, 33065
- ENT Associates of South Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be ≥21 years of age.
- Has been diagnosed with chronic nonallergic or allergic rhinitis.
- Have moderate to severe symptoms of rhinorrhea (individual reflective Total Nasal Symptoms Score [rTNSS] symptom rating of 2 or 3), mild to severe symptoms of nasal congestion (individual rTNSS symptom rating of 1, 2, or 3), and a minimum total rTNSS of 4 (out of 12) at baseline.
- Have an allergy test (by skin prick or intradermal testing or by validated in vitro tests for specific Immunoglobin E [IgE]) on file within 12 months of the baseline visit.
- Be an appropriate candidate for bilateral ClariFix treatment performed under local anesthesia.
- Be willing and able to comply with all study elements, as indicated by their written informed consent.
- Be willing and able to comply with all study elements and provide written consent.
Exclusion Criteria:
- Have clinically significant anatomic obstructions that in the investigator's opinion limit access to the posterior nose, including but not limited to severe septal deviation or perforation, nasal polyps, and/or sinonasal tumor.
- Have had previous sinus or nasal surgery within 6 months of study enrollment.
- Have previously undergone cryotherapy or other surgical interventions for rhinitis.
- Have an active nasal or sinus infection.
- Have rhinitis symptoms that are primarily due to seasonal allergies.
- Have plans to (or otherwise anticipates the need to) undergo an ENT (ear, nose, throat) procedure concurrently or within 3 months after the study procedure.
- Is on prescribed anticoagulants (eg, warfarin, Plavix) or 325 mg aspirin that cannot be discontinued before the procedure (81 mg aspirin and herbal supplements are acceptable).
- Be unable to discontinue ipratropium bromide (IB) at least 14 days before baseline and through the 90-day follow-up visit.
- Have a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months.
- Have a history of rhinitis medicamentosa.
- Have had previous head and/or neck irradiation.
- Have an allergy or intolerance to local anesthetic agents.
- Have cryoglobulinemia, paroxysmal cold hemoglobinuria, cold urticaria, Raynaud's disease, and/or open and/or infected wounds at or near the target tissue.
- Have a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data.
- Be participating in another clinical research study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ClariFix
Cryotherapy of the nasal passages with the ClariFix device.
|
Bilateral freeze ablation of nasal tissue using the ClariFix device.
|
Sham Comparator: Sham
Sham cryotherapy of the nasal passages with the ClariFix device
|
Bilateral sham ablation procedure using the ClariFix device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rTNSS Responder Rate
Time Frame: 90-days post treatment
|
Responders are defined as participants with a 30% or greater reduction in reflective Total Nasal Symptom Score (rTNSS) relative to baseline. The active treatment will be compared with the sham treatment. The reflective Total Nasal Symptom Score (rTNSS) is a validated PRO consisting of 4 nasal symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing that are assessed over the previous 2-week period. Each symptom is rated on a scale of 0 (no symptoms) to 3 (severe symptoms) and the scores are summed to provide a total rTNSS with a possible range of 0 to 12. |
90-days post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
rTNSS Responder Rate
Time Frame: Through 12 months post treatment
|
Mean change from baseline in the rTNSS.
The reflective Total Nasal Symptom Score (rTNSS) is a validated PRO consisting of 4 nasal symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing that are assessed over the previous 2-week period.
Each symptom is rated on a scale of 0 (no symptoms) to 3 (severe symptoms) and the scores are summed to provide a total rTNSS with a possible range of 0 to 12.
|
Through 12 months post treatment
|
Change in Total RQLQ(S)
Time Frame: Through 12 months post treatment
|
Mean change from baseline in the Standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) score. The RQLQ(S) is a validated PRO that measures functional impairments due to allergic or non-allergic rhinoconjunctivitis. The assessment consists of 28 questions related to nose symptoms, eye symptoms, non-eye/nose symptoms, sleep problems, practical problems, activity limitations, and emotional function. Each item is scored from 0 (no impairment) to 6 (severely impaired). An overall score is calculated from the mean of the 28 item responses. Domain scores are the mean of the item scores within that domain. |
Through 12 months post treatment
|
Patient Satisfaction Questionnaire
Time Frame: Through 12 months post treatment
|
Percent of participants indicating satisfaction with the procedure outcome.
The satisfaction questionnaire consists of 3 questions that the participant answers at each follow-up visit.
The questions indicate whether the participant is satisfied with the procedure outcome, whether the participant would undergo the procedure again for similar results, and whether the participant would recommend the procedure to family or friends with a similar condition.
For each item the participant indicates agreement/disagreement with each statement.
|
Through 12 months post treatment
|
Serious Device- and/or Procedure-related Adverse Events
Time Frame: Through 12 months post procedure
|
The number of participants with one or more serious adverse events that are possibly, probably, or definitely related to the ClariFix device and/or procedure.
|
Through 12 months post procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anthony DelSignore, MD, Ichan School of Medicine, Mount Sinai, New York, NY
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4666-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Rhinitis
-
Meda PharmaceuticalsCompletedChronic Allergic Rhinitis | Nonallergic RhinitisUnited States
-
Jantar GmbHTerminatedChronic Rhinitis | Chronic Sinus CongestionSwitzerland
-
Organon and CoCompleted
-
University of South FloridaTerminated
-
Neurent MedicalCompletedChronic RhinitisUnited States
-
Arrinex, Inc.Completed
-
Arrinex, Inc.CompletedChronic RhinitisUnited States
-
Arrinex, Inc.Completed
-
Zheng Liu ENTPeking Union Medical College; First Affiliated Hospital of Xinjiang Medical... and other collaboratorsNot yet recruiting
Clinical Trials on ClariFix cryotherapy
-
Arrinex, Inc.Completed
-
Arrinex, Inc.Completed
-
Arrinex, Inc.CompletedChronic RhinitisUnited States
-
Cairo UniversityNot yet recruiting
-
Creighton UniversityCompleted
-
Hanyang University Seoul HospitalCompletedCryotherapy EffectKorea, Republic of
-
Ondokuz Mayıs UniversityRecruitingPain, Postoperative | Pulpitis | Caries; DentinTurkey
-
CSA Medical, Inc.WithdrawnLung Diseases, Obstructive | Airway Obstruction | Lung Disease Airways | Airway; Obstruction, With Emphysema
-
Unity Health TorontoRecruitingRetinal Detachment | MetamorphopsiaCanada